{"id":62406,"date":"2026-04-04T22:24:11","date_gmt":"2026-04-04T14:24:11","guid":{"rendered":"https:\/\/flcube.com\/?p=62406"},"modified":"2026-04-04T22:24:12","modified_gmt":"2026-04-04T14:24:12","slug":"binhui-biopharmaceutical-submits-hong-kong-ipo-prospectus-with-pioneering-oncolytic-virus-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62406","title":{"rendered":"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline"},"content":{"rendered":"\n<p><strong>Binhui Biopharmaceutical Co., Ltd.<\/strong> has submitted its <strong>initial public offering (IPO) prospectus<\/strong> to the <strong>Hong Kong Stock Exchange<\/strong>, seeking listing on the bourse as a specialized biotechnology company focused exclusively on <strong>oncolytic virus therapies<\/strong> for cancer treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-strategic-focus\">Company Profile &amp; Strategic Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Binhui Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2010<\/td><\/tr><tr><td><strong>Headquarters<\/strong><\/td><td>Wuhan, China<\/td><\/tr><tr><td><strong>Core Focus<\/strong><\/td><td>Discovery, development, and commercialization of oncolytic virus therapies<\/td><\/tr><tr><td><strong>Listing Venue<\/strong><\/td><td>Hong Kong Stock Exchange (application submitted)<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Oncology<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Oncolytic virus engineering and optimization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-portfolio-overview\">Pipeline Portfolio Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Development Stage<\/th><th>Candidates<\/th><th>Key Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Clinical-Stage<\/strong><\/td><td>BS001 (OH2 Injection)<\/td><td>HSV-2 based oncolytic virus, dual mechanism<\/td><\/tr><tr><td><strong>Clinical-Stage<\/strong><\/td><td>BS006<\/td><td>Oncolytic virus candidate (details undisclosed)<\/td><\/tr><tr><td><strong>Preclinical-Stage<\/strong><\/td><td>BR003<\/td><td>Early development candidate<\/td><\/tr><tr><td><strong>Preclinical-Stage<\/strong><\/td><td>BS051<\/td><td>Early development candidate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-product-bs001-oh2-injection-profile\">Core Product \u2013 BS001 (OH2 Injection) Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Viral Platform:<\/strong> Novel oncolytic virus candidate based on <strong>herpes simplex virus type 2 (HSV-2)<\/strong><\/li>\n\n\n\n<li><strong>Dual Mechanism of Action:<\/strong><\/li>\n\n\n\n<li><strong>Direct Oncolysis:<\/strong> Selective replication in tumor cells leading to direct cell lysis<\/li>\n\n\n\n<li><strong>Immune Activation:<\/strong> Secretion of <strong>human granulocyte-macrophage colony-stimulating factor (hGM-CSF)<\/strong> to induce systemic anti-tumor immune response<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Clinical trial approvals secured in both <strong>China<\/strong> and the <strong>United States<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> HSV-2 backbone may offer improved safety profile and enhanced tumor selectivity compared to HSV-1 based platforms<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-positioning-amp-competitive-landscape\">Market Positioning &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncolytic Virus Market:<\/strong> Emerging therapeutic class with limited approved products globally, creating significant first-mover opportunities<\/li>\n\n\n\n<li><strong>China Innovation Focus:<\/strong> Aligns with national biopharmaceutical innovation priorities and supportive regulatory environment for novel cancer therapies<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> U.S. clinical trial approval demonstrates international regulatory strategy and potential for global commercialization<\/li>\n\n\n\n<li><strong>Specialized Expertise:<\/strong> Pure-play oncolytic virus focus distinguishes Binhui from diversified biopharmaceutical companies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-thesis-amp-growth-strategy\">Investment Thesis &amp; Growth Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Technology:<\/strong> Success with BS001 validates proprietary oncolytic virus engineering platform for future pipeline expansion<\/li>\n\n\n\n<li><strong>Dual Revenue Streams:<\/strong> Potential for both monotherapy applications and combination regimens with existing immunotherapies<\/li>\n\n\n\n<li><strong>Capital Markets Access:<\/strong> Hong Kong listing would provide funding for late-stage clinical development and commercial infrastructure<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Oncolytic viruses represent attractive assets for strategic partnerships with major pharmaceutical companies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-risk-considerations-amp-development-timeline\">Risk Considerations &amp; Development Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Validation:<\/strong> Oncolytic virus efficacy and safety require robust clinical demonstration across multiple tumor types<\/li>\n\n\n\n<li><strong>Manufacturing Complexity:<\/strong> Viral therapy production presents unique manufacturing and quality control challenges<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Evolving regulatory frameworks for oncolytic viruses may impact development timelines<\/li>\n\n\n\n<li><strong>Commercial Adoption:<\/strong> Physician education and treatment center infrastructure required for successful market penetration<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Binhui&#8217;s IPO plans, clinical development programs, regulatory approvals, and business strategy. Actual results may differ materially due to risks including regulatory decisions, clinical trial outcomes, market conditions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26040203644_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26040203644_c.\"><\/object><a id=\"wp-block-file--media-028d1aa1-668b-4503-8b74-ddd86595e552\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26040203644_c.pdf\">sehk26040203644_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26040203644_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-028d1aa1-668b-4503-8b74-ddd86595e552\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62408,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2601,72],"class_list":["post-62406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-binhui-biopharmaceutical","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, seeking listing on the bourse as a specialized biotechnology company focused exclusively on oncolytic virus therapies for cancer treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62406\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline\" \/>\n<meta property=\"og:description\" content=\"Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, seeking listing on the bourse as a specialized biotechnology company focused exclusively on oncolytic virus therapies for cancer treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62406\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-04T14:24:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-04T14:24:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0403.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline\",\"datePublished\":\"2026-04-04T14:24:11+00:00\",\"dateModified\":\"2026-04-04T14:24:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406\"},\"wordCount\":440,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0403.webp\",\"keywords\":[\"Binhui Biopharmaceutical\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62406#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62406\",\"name\":\"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0403.webp\",\"datePublished\":\"2026-04-04T14:24:11+00:00\",\"dateModified\":\"2026-04-04T14:24:12+00:00\",\"description\":\"Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, seeking listing on the bourse as a specialized biotechnology company focused exclusively on oncolytic virus therapies for cancer treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62406\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0403.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0403.webp\",\"width\":1080,\"height\":608,\"caption\":\"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62406#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, seeking listing on the bourse as a specialized biotechnology company focused exclusively on oncolytic virus therapies for cancer treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62406","og_locale":"en_US","og_type":"article","og_title":"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline","og_description":"Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, seeking listing on the bourse as a specialized biotechnology company focused exclusively on oncolytic virus therapies for cancer treatment.","og_url":"https:\/\/flcube.com\/?p=62406","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-04T14:24:11+00:00","article_modified_time":"2026-04-04T14:24:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0403.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62406#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62406"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline","datePublished":"2026-04-04T14:24:11+00:00","dateModified":"2026-04-04T14:24:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62406"},"wordCount":440,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62406#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0403.webp","keywords":["Binhui Biopharmaceutical","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62406#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62406","url":"https:\/\/flcube.com\/?p=62406","name":"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62406#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62406#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0403.webp","datePublished":"2026-04-04T14:24:11+00:00","dateModified":"2026-04-04T14:24:12+00:00","description":"Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, seeking listing on the bourse as a specialized biotechnology company focused exclusively on oncolytic virus therapies for cancer treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62406#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62406"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62406#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0403.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0403.webp","width":1080,"height":608,"caption":"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62406#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0403.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62406"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62406\/revisions"}],"predecessor-version":[{"id":62410,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62406\/revisions\/62410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62408"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}